Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Novo Nordisk A/S (NVO) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 85,751,600
  • Shares Outstanding, K 2,527,310
  • Annual Sales, $ 16,060 M
  • Annual Income, $ 5,187 M
  • 36-Month Beta 0.82
  • Price/Sales 5.34
  • Price/Book 13.83

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.89 +14.06%
on 11/23/16
35.26 -0.07%
on 12/06/16
+0.88 (+2.57%)
since 11/04/16
3-Month
30.89 +14.06%
on 11/23/16
46.55 -24.31%
on 09/16/16
-10.77 (-23.40%)
since 09/06/16
52-Week
30.89 +14.06%
on 11/23/16
59.00 -40.28%
on 12/30/15
-21.80 (-38.22%)
since 12/04/15

Most Recent Stories

More News
Lilly: Jardiance Label to Add Cardiovascular Indication

Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's...

Novo Nordisk Files Regulatory Application for Semaglutide

Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile

Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.

New Strong Sell Stocks for November 28th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday

Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod

Novo Nordisk A/S (NVO) received favorable news with the FDA approving its new drug application for Xultophy 100/3.6.

Novo Nordisk Receives FDA Approval for Xultophy® 100/3.6 (insulin degludec and liraglutide injection)

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy® 100/3.6 (insulin degludec 100 units/mL and...

Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer

Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team....

5 Pharma Stocks in Focus on World Diabetes Day

The diabetes market is highly crowded given the presence of companies like Novo Nordisk (NVO), Sanofi and Merck among others.

ComplianceOnline Announces On-Demand Seminar on 21 CFR Part 11 Compliance to be Held in CA and PA

ComplianceOnline's on-demand seminar on 21 CFR Part 11 Compliance for SaaS/Cloud Applications returns to California and Philadelphia in 2017. The 2016 sold-out event was attended by various healthcare...

Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp(R) (fast-acting insulin aspart) for the treatment of diabetes

Bagsvaerd, Denmark, 11 November 2016 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 34.65
1st Resistance Point 34.53
Last Price 35.15
1st Support Level 34.24
2nd Support Level 34.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.